Spectrum Pharmaceuticals, Inc. (SPPI)
(Delayed Data from NSDQ)
$9.80 USD
+0.50 (5.38%)
Updated May 3, 2019 04:00 PM ET
After-Market: $9.81 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[SPPI]
Reports for Purchase
Showing records 1 - 20 ( 432 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Acquisition by Assertio Holdings; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Preliminary Rolvedon Sales Exceed Expectations; We Are Raising Our Revenue Estimates
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Rolvedon Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Poziotinib Receives CRL From the FDA; Lowering PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
3Q22 Results; Rolvedon Commercial Launch Underway; Poziotinib PDUFA Date on Thanksgiving Day
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Industry: Medical - Drugs
ODAC Votes Against Poziotinib; Debt Deal Announced; Lower PT by $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Briefing Documents For Upcoming Poziotinib ODAC Meeting Point to a Contentious Meeting; Lower PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
A Great Weekend For Spectrum With Rolvedon Approved on Friday Evening and Positive Pozi Data Reported on Saturday
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
2Q22 Results; Two PDUFA Dates in 2H22; ODAC Meeting on September 22, 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Exploratory Biomarker Data For Poziotinib to Be Presented At ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
1Q22 Results: Two Potential Approvals in 2H22; ODAC Meeting Set for Poziotinib in September
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Resubmitted BLA for Eflapegrastim Accepted by FDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Industry: Medical - Drugs
4Q21 Results; Eflapegrastim BLA Resubmitted to the FDA; Poziotinib PDUFA in November
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E